MarketInOut Stock Screener Log In | Sign Up

Atara Biotherapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/20/2026
Atara Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization68.87 mln
Float7.03 mln
Earnings Date03/01/2027

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

6.34
Highly suspicious

Relative Strength

19 / 100
Significantly lagging

Pre-Tax Margin

-369%
Severely loss-making

ROE

38.79
Very strong

Altman Z-Score

-154
Deeply distressed

Business Description

Founded in 2012 and based in Thousand Oaks, California, Atara Biotherapeutics is a clinical-stage company working to create new treatment options for patients with cancer and immune system disorders. Its most advanced program, tabelecleucel, uses the body's own immune cells to fight diseases caused by the Epstein-Barr virus, including a serious condition that can develop after organ or stem cell transplants. The company is also advancing a next-generation cell therapy aimed at certain blood cancers and autoimmune conditions, and conducts its research in partnership with two leading medical institutions.

Key Fundamentals

EPS-1.12
ROE38.79
RPS0.27
ROIC-87.38
ROA-65.42
Interest Cover-7.11
EBITDA, mln-12.60
EV / EBITDA-13.06
EV / EBIT-12.97
Revenue, mln3.96
EV / Revenue41.52

Quote Details

Last 6.33
Change -0.01 (-0.16%)
Open 6.25
Volume 36,417
Turnover 230,520
Average Volume 24,863

Financial Ratios

Pre-Tax Profit Margin-369
Current Ratio1.72
Price / Sales21.32

Financial Strength

Altman Z-Score-154
Piotroski F-Score 3 / 9
Beneish M-Score6.34
Short Ratio9.41
Short % of Float3.95

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -17.79% 19 / 100   
1 Month -32.87% 16 / 100   
2 Months -24.28% 32 / 100   
6 Months -35.41% 25 / 100   
1 Year -53.93% 19 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog